SG11202109097UA - Materials and methods for enhanced treatment and prevention of biofilms - Google Patents

Materials and methods for enhanced treatment and prevention of biofilms

Info

Publication number
SG11202109097UA
SG11202109097UA SG11202109097UA SG11202109097UA SG11202109097UA SG 11202109097U A SG11202109097U A SG 11202109097UA SG 11202109097U A SG11202109097U A SG 11202109097UA SG 11202109097U A SG11202109097U A SG 11202109097UA SG 11202109097U A SG11202109097U A SG 11202109097UA
Authority
SG
Singapore
Prior art keywords
biofilms
prevention
materials
methods
enhanced treatment
Prior art date
Application number
SG11202109097UA
Inventor
Sean Farmer
Ken Alibek
Original Assignee
Locus Ip Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Ip Co Llc filed Critical Locus Ip Co Llc
Publication of SG11202109097UA publication Critical patent/SG11202109097UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SG11202109097UA 2019-03-15 2020-03-13 Materials and methods for enhanced treatment and prevention of biofilms SG11202109097UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819000P 2019-03-15 2019-03-15
US201962846079P 2019-05-10 2019-05-10
PCT/US2020/022591 WO2020190699A1 (en) 2019-03-15 2020-03-13 Materials and methods for enhanced treatment and prevention of biofilms

Publications (1)

Publication Number Publication Date
SG11202109097UA true SG11202109097UA (en) 2021-09-29

Family

ID=72520453

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109097UA SG11202109097UA (en) 2019-03-15 2020-03-13 Materials and methods for enhanced treatment and prevention of biofilms

Country Status (12)

Country Link
US (1) US20220142988A1 (en)
EP (1) EP3937634A4 (en)
JP (1) JP2022525762A (en)
KR (1) KR20210129725A (en)
CN (1) CN113873883A (en)
AU (1) AU2020241243A1 (en)
BR (1) BR112021018306A2 (en)
CA (1) CA3132821A1 (en)
IL (1) IL286437A (en)
MX (1) MX2021011147A (en)
SG (1) SG11202109097UA (en)
WO (1) WO2020190699A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240188564A1 (en) * 2021-03-26 2024-06-13 Suncor Energy Inc. Antibiofilm formulations and methods
CN117838736B (en) * 2024-01-29 2024-06-14 吉林省农业科学院(中国农业科技东北创新中心) Application of bacillus coagulans JA845 in preparation of medicines for preventing and/or treating atherosclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI103056B1 (en) * 1996-08-16 1999-04-15 Orion Yhtymae Oy Method and test kit for pre-treatment of the sampling surface
US20020123077A1 (en) * 2000-09-29 2002-09-05 O'toole George A. Novel compounds capable of modulating biofilms
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
JP2012072179A (en) * 2005-08-30 2012-04-12 Kao Corp Biofilm inhibitor
US8357385B2 (en) * 2008-04-07 2013-01-22 Interface Biologics Inc. Combination therapy for the treatment of bacterial infections
CA2744172A1 (en) * 2008-12-10 2010-06-17 Pan-Eco S.A. Biosurfactant composition produced by a new bacillus licheniformis strain, uses and products thereof
US9028878B2 (en) * 2009-02-03 2015-05-12 Microbion Corporation Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
US8987217B2 (en) * 2010-01-12 2015-03-24 The General Hospital Corporation Modified saponins for the treatment of fungal infections
US20110306569A1 (en) * 2010-06-11 2011-12-15 Oregon State University Rhamnolipid biosurfactant from pseudomonas aeruginosa strain ny3 and methods of use
WO2014120247A1 (en) * 2013-02-02 2014-08-07 Polytechnic Institute Of New York University Modified sophorolipids combinations as antimicrobial agents
CN104233331B (en) * 2014-09-11 2016-06-29 南京农业大学 The sweep-out method of food rustless steel operated implement surface pathogenic bacterium biology Mycoderma
US20180310566A1 (en) * 2017-04-29 2018-11-01 Nevada Naturals Inc. Biofilm Penetrating Compositions and Methods

Also Published As

Publication number Publication date
IL286437A (en) 2021-10-31
WO2020190699A1 (en) 2020-09-24
MX2021011147A (en) 2021-10-22
EP3937634A1 (en) 2022-01-19
CN113873883A (en) 2021-12-31
AU2020241243A1 (en) 2021-09-09
JP2022525762A (en) 2022-05-19
US20220142988A1 (en) 2022-05-12
CA3132821A1 (en) 2020-09-24
EP3937634A4 (en) 2022-11-09
BR112021018306A2 (en) 2022-01-25
KR20210129725A (en) 2021-10-28

Similar Documents

Publication Publication Date Title
GB201804514D0 (en) Treatment of pyroptosis
IL292810A (en) Therapeutic compounds and methods of use
IL272321A (en) Methods and compositions for treatment of amyloid deposition diseases
IL291362A (en) Treatment of syngap1 encephalopathy
IL286437A (en) Materials and methods for enhanced treatment and prevention of biofilms
IL286697A (en) Neuregulin-4 compounds and methods of use
IL275925A (en) Prevention and treatment of organ fibrosis
GB201804515D0 (en) Treatment of necroptosis
IL273850A (en) Compositions and methods for treatment of fibrosis
IL276905A (en) Treatment and prevention of pre-eclampsia
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
GB201913122D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB2589398B (en) Compounds and methods of use
EP3377062C0 (en) Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
IL271727A (en) Method of treatment and dosage forms thereof
GB201907305D0 (en) Treatment of conditions
GB201913124D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) Compositions and methods for treatment of cholangiocarcinoma
GB201810923D0 (en) Compositions and method of treatment
IL256675A (en) Methods and compositions for prevention and treatment of pressure ulcers
GB202210704D0 (en) Biofilm prevention and treatment
GB201901219D0 (en) Compositions and methods of treatment
IL290983A (en) Methods of treatment
GB201815000D0 (en) Treatment of hypothroidism and related conditions
GB201907609D0 (en) Treatment and prevention of malaria